Mission Bio has completed the first tech transfer of a clinical trial-, good manufacturing practices (GMP)-ready cell and gene therapy (CGT) assay from its Tapestri platform to Avance Biosciences, to assess transduction efficiency for an autologous cell therapy currently under development.
